Burning mouth syndrome
Conditions
Interventions
Experimental Group:All patients were treated with lipoic acid capsule (Fu Ding Le, Chinese Medicine approval number H20133253, Penglai Nuokang Pharmaceutical Co., LTD.), 0.3 g/ capsule, once a day, 0.
Control group:All patients were treated with conventional therapy, oral oryzanol tablets (Sinopharm approved name H22024804, Jilin Fultai Pharmaceutical Co., LTD.), 10 mg/ time, 3 times /d
Vitamin B2 tablets (Chinese Medicine approved name H61021467, Shaanxi Sun Simiao High-tech Pharmaceutical Co., LTD.) orally, 5 mg/ time, 3 times/day
Vitamin E capsule (Chinese Medicine approved name H22021973, Jilin Wantong Pharmaceutical Co., LTD.) was taken orally, 100 mg/ time, once a day.
Sponsors
Sinopharm First Machinery Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. BMS was diagnosed according to the International Classification of Headache Disorders (pain characterized by burning sensation and dryness of oral mucosa, lasting >=2 h/d for more than 3 months; 2. Oral mucosal appearance and clinical examination including sensory tests were normal; 3. Asymptomatic pathogenic disease); 4. Age >=18 years old; 5. No organic lesions in the oral cavity; 6. All subjects gave informed consent for this study.
Exclusion criteria
Exclusion criteria: 1. Patients with malignant tumors; 2. Patients with other oral mucosal diseases; 3. Patients with hematological and immune diseases; 4. Severe heart, liver and kidney dysfunction; 5. Taking hormones and immunosuppressants in the past month; 6. Pregnant and lactating women; 7. Patients with incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue scoring; | — |
Countries
China
Contacts
Public ContactWang Bo
Sinopharm First Machinery Hospital
Outcome results
None listed